In re Axsome Therapeutics, Inc. Securities Litigation

Track this case

Case Number:

1:22-cv-03925

Court:

New York Southern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Lorna G. Schofield

Firms

Companies

Sectors & Industries:

  1. September 23, 2025

    Axsome Settles Investors' Drug Approval Suit For $7.8M

    Biopharmaceutical company Axsome Therapeutics Inc. and its shareholders have asked a New York federal court to approve a $7.75 million settlement to resolve investors' claims that Axsome hid issues related to gaining regulatory approval for its migraine drug.

  2. September 26, 2023

    Axsome Beats Securities Suit Over Migraine Drug, For Now

    A New York federal judge on Monday tossed a proposed securities class action alleging that biopharmaceutical company Axsome hid issues about its migraine drug, leading to a significant stock price drop, saying the lead plaintiff suffered no loss since he sold his shares at an inflated price.